ArticleAntimicrobial agents and chemotherapy1998
Susceptibilities of Legionella spp. to newer antimicrobials in vitro.
Article in Antimicrobial agents and chemotherapy, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Efficacy and safety of linezolid for the treatment of infections in children: a meta-analysis.European journal of pediatrics · 2014Pooled it
- Guideline
- Controlled trial of a 5-day course of telithromycin versus doxycycline for treatment of mild to moderate scrub typhus.Antimicrobial agents and chemotherapy · 2007Trial
- Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.BMC infectious diseases · 2005Trial
- Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.Antimicrobial agents and chemotherapy · 2002Trial
- Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).Antimicrobial agents and chemotherapy · 2001Trial
- Antimicrobial Susceptibility Determination of Less Frequently IsolatedAntibiotics (Basel, Switzerland) · 2025Article
- Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement.Molecular diversity · 2024Review
- Carbohydrate-based drugs launched during 2000Acta pharmaceutica Sinica. B · 2022Review
- Clinical Utility of Lefamulin: If Not Now, When?Current infectious disease reports · 2020Review
- Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data.BMC infectious diseases · 2015Article
- [Guidelines for the management of community pneumonia in adult who needs hospitalization].Medicina intensiva · 2005Article
- Review
- Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.Antimicrobial agents and chemotherapy · 2002Article
- A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses · 2001Article
- Telithromycin.Drugs · 2001Article
- Review
- Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.Antimicrobial agents and chemotherapy · 2001Article
- Review
- Bactericidal activities of antibiotics against intracellular Francisella tularensis.Antimicrobial agents and chemotherapy · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vitro activities of 13 antimicrobial agents against 30 strains of Legionella spp. were determined. Rifapentine, rifampin, and clarithromycin were the most potent agents (MICs at which 90% of isolates are inhibited [MIC90s], < or = 0.008 microgram/ml). The ketolide HMR 3647 and the fluoroquinolones levofloxacin and BAY 12-8039 (MIC90s, 0.03 to 0.06 microgram/ml) were more active than erythromycin A or roxithromycin. The MIC90s of dalfopristin-quinupristin and linezolid were 0.5 and 8 micrograms/ml, respectively. Based on class characteristics and in vitro activities, several of these agents may have potential roles in the treatment of Legionella infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.